Rheumatoid Arthritis

      RT @RichardPAConway: Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly the

      Richard Conway RichardPAConway

      3 years 6 months ago
      Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M
      RT @drdavidliew: Long-term low-dose steroids for RA: can it be weaned?

      Weaning after 2y of blinded add-on in RA:
      either

      David Liew drdavidliew

      3 years 6 months ago
      Long-term low-dose steroids for RA: can it be weaned? Weaning after 2y of blinded add-on in RA: either PNL 5mg/d or placebo No substantial evidence of adrenal insufficiency - symptoms same - cortisol/ACTH same It's never too late to wean the pred! OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb
      RT @ericdeinmd: #EULAR2022 OP0274
      Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
      ⭐

      Eric Dein ericdeinmd

      3 years 6 months ago
      #EULAR2022 OP0274 Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease: ⭐️9% with RA, 6% with PsA and AS in Western Australia ⭐️Decrease overall since 1985, but recent increase ⭐️Sharp rise of mycotic infections ⭐️No PJP, likely due to ppx @Rheumnow
      RT @RichardPAConway: Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture

      Richard Conway RichardPAConway

      3 years 6 months ago
      Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
      RT @drdavidliew: RA & dementia - it's getting more damning

      RA dementia risk: HR 1.25
      from Korean nationwide data: R

      David Liew drdavidliew

      3 years 6 months ago
      RA & dementia - it's getting more damning RA dementia risk: HR 1.25 from Korean nationwide data: RA n=138,592 this follows @MyasoedovaElena's data RA systemic inflamm leading to dementia (AD, vascular)? Need to understand if any DMARD protective OP0271 #EULAR2022 @RheumNow https://t.co/4V7fOtVlnj
      RT @ericdeinmd: #EULAR2022 OP0275: RA-ILD after transplant by @AARazmjou
      ⭐️UIP #1 cause RA-ILD, worst prognosis - 6

      Eric Dein ericdeinmd

      3 years 6 months ago
      #EULAR2022 OP0275: RA-ILD after transplant by @AARazmjou ⭐️UIP #1 cause RA-ILD, worst prognosis - 68% of transplanted pts ⭐️UIP seen in 88% of deceased patients, 56% of living ⭐️Median survival 5.3 years @RheumNow https://t.co/tGBQ5GBlVg
      RT @ericdeinmd: #EULAR2022 OP0273
      Difficult to treat RA (D2TRA):
      ⭐️Lower socioeconomic treatment
      ⭐️RF positivity

      Eric Dein ericdeinmd

      3 years 6 months ago
      #EULAR2022 OP0273 Difficult to treat RA (D2TRA): ⭐️Lower socioeconomic treatment ⭐️RF positivity ⭐️Higher inflammatory markers ⭐️ILD ⭐️Lower proportion on MTX, better response to JAKi and RTX @RheumNow
      GLORIA trial presented by Martin Boxers. 2 yr RCT, 5mg Pred vs. PBO shows DAS28 benefit (-0.37 to -0.62) & -1.7 bett

      Dr. John Cush RheumNow

      3 years 6 months ago
      GLORIA trial presented by Martin Boxers. 2 yr RCT, 5mg Pred vs. PBO shows DAS28 benefit (-0.37 to -0.62) & -1.7 better X-ray (vs PBO) at 2yrs. BUT signif more harm (AE) RR 1.24; mostly infx. Is this a good trade off? Abst# OP0263 #EULAR2022 https://t.co/kBiRYxXXZe
      RT @synovialjoints: Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that

      Dr. Antoni Chan synovialjoints

      3 years 6 months ago
      Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh
      RT @ericdeinmd: #EULAR2022 OP0276: What do patients want for preventative interventions for RA?
      ⭐️Survey of 1st degr

      Eric Dein ericdeinmd

      3 years 6 months ago
      #EULAR2022 OP0276: What do patients want for preventative interventions for RA? ⭐️Survey of 1st degree relatives of RA pts (at risk) vs general pop were similar ⭐️'Hypothetical' treatment profile best aligned to abatacept @Rheumnow https://t.co/r4y7SZbjTA
      RT @AurelieRheumo: Survival of RA-ILD pts w/ lung 🫁 transplantation

      Retrospective single centre study

      *Mortality 36

      Aurelie Najm AurelieRheumo

      3 years 6 months ago
      Survival of RA-ILD pts w/ lung 🫁 transplantation Retrospective single centre study *Mortality 36% *Usual Interstitial Pneumonia worst prognosis w/ HR 7.13 (did not reach significance, small cohort) *Survival time comparable to other lung Tx cohorts #EULAR2022 OP0275 @RheumNow https://t.co/LslPxyXJCp
      Another Take on the 2022 EULAR RA Treatment Guidelines
      • Dr. Peter Nash
      3 years 6 months ago
      acr_session2.jpeg
      EULAR 2022 – Day 2 Report
      3 years 6 months ago
      A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
      RT @uptoTate: To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between c

      Dr. Rachel Tate uptoTate

      3 years 6 months ago
      To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog @RheumNow https://t.co/0cTep6MHLu
      woman-1284353_640.jpg
      Babies! Safety and Outcomes Data on Pregnancies
      3 years 6 months ago
      EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye because they can potentially impact medical practice.

      Catch up on Conference Podcasts

      ×